We assessed, in 98 patients with cancer, the diagnostic value of measuring serum alkaline phosphatase, 5'-nucleotidase, -y-glutamyltransferase, and glutamate dehydrogenase activities as an aid to detection of liver metastases. All four enzymes showed diagnostic value, but 5'-nucleotidase appeared to have the greatest. It showed the lowest false-positive results (7.4%) with the highest predictive value of a positive test (85.7%) and agreement (81.3%). -y-Glutamyltransferase showed the lowest proportion of false-negative results (2.8%), but was the least specific (35% false-positive results). Analysis of various test combinations showed that the best agreement (77.5%) was obtained when the patients were divided into those who had no or only one abnormal test result, and those who had two or more abnormal test results. However, this was not better than the agreement for 5'-nucleotidase alone (81.3%). The agreement of 5'-nucleotidase and y-glutamyltransferase (i.e., both tests were positive or negative) was excellent (91.4%), but such agreement included only 67% of the patients with liver metastases.
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The diagnosis of hepatic metastases has therapeutic and prognostic significance in clinical medicine. Various enzyme activity measurements in serum have been used to help detect metastases to the liver. Such determinations have the advantage of being simple and noninvasive.
Alkaline phosphatase, leucine aminopeptidase, lactate dehydrogenase, and aspartate aminotransferase are among the enzymes evaluated most extensively (1, 2) . Recently, 5'-nucleotidase, "y-glutamyltransferase, and glutamate dehydrogenase have been suggested as more specific and sensitive enzymes for use in detecting hepatic metastases (1) (2) (3) (4) (5) (6) . The present study was undertaken to compare the diagnostic value of the last three enzymes and of alkaline phosphatase, and to see if sensitivity or specificity could be improved with combined determinations of the activity of more than one of these enzymes.
Of 116 consecutive new patients admitted to the Medical Oncology Service of the University of Minnesota Hospitals, 98 met the following criteria and were included in the study: histologically proven malignancy with no prior chemotherapy, no recent jaundice or hepatic disease, and no bone fracture or benign bone disorders in the previous six months. Table 1 lists the type and frequency of the various tumors present in our patients. More than 40% of the patients had breast and gastrointestinal cancers, which are known to metastasize frequently to the liver.
Alkaline phosphatase (EC 3.1.3.1) was determined by the method of Bowers and McComb (7), 5'-nucleotidase (EC 3.1.3.5) by the method of Belfield and Goldberg (8) plus biopsy, and in two patients by liver biopsy alone. Fifty-five patients had no evidence of hepatic metastases. There were three patients with questionable liver metastases onwhom only liver scan was performed, and these were excluded fromanalysis. Clinically detectable liver enlargement was found in 23 of the 40 patients with hepatic metastases. In addition, bone scan, roentgenograms of the skeleton, bone marrow biopsy, or some combination of these tests was used to detect skeletal metastases. Bone metastases were documented in 33 patients. Six patients had questionable bone lesions, 59 had no evidence of bone involvement, and nine had both skeletal and hepatic involvement. Table 2 shows the general form of the data and the computations used. The diagnostic value of the tests is expressed as percent agreement, percent false-positive, percent false-negative, and predictive value of a positive test (PV+). "Percent agreement" denotes the probability that an enzyme test shows correctly the presence or absence of hepatic metastases. "Percent false-negative" is defined as the proportion of patients with hepatic metastases who had normal values for these enzyme activities. "Percent false-positive" denotes the proportion of patients without metastases who had an abnormal enzyme value. "PV+" denotes the probability that a patient with an abnormal enzyme value has hepatic metastases. Table 3 shows the serum enzyme activitiesof the 95 cancer patients designated as normal or abnormal and correlated with the presence or absence of liver metastases. Table 4 shows the diagnostic value of each of the four enzymes calculated from these data, as illustrated in Table 2 . With abnormal values for alkaline phosphatase in 49 patients, of whom 31 had liver metastases, the PV+ was 63.3%.
Results

5'-Nucleotidase
Above-normal activity of this enzyme in the serum of patients with liver metastases was observed in 24 of 37 patients, normal values were seen in 50 of 54 patients without liver metastases-an agreement of 81.3%. There were 13 patients (35.1%) with false-negative results and only four (7.4%) patients with false-positive results. Of the patients with abnormal 5'-nucleotidase activity, 24 had liver metastases (PV+ = 85.7%).
'y-Glutamyltransf erase This activity in serum was above normal in 35 of 36 patients with liver metastases, normal in 30 of 55 patients without metastases-an agreement of 71.4%. However, only one patient (2.8%) had a false-negative result, while 25 patients (45.5%) had false-positive results. Of the 60 patients who showed abnormal enzyme activity, 35 had liver metastases (PV+ = 58.3%).
Glutamate Dehydrogenase
The activity of this enzyme in serum reflected correctly the presenceor absence of liver metastases in 62 of 92 patients, an agreement of 67.4%. However, the incidence of both false-negative and false-positive results was high (29.7 and 34.5%, respectively).
Of 45 patients who had abnormal serum glutamate dehydrogenase activity, 26 had liver metastases, a PV+ of 57.8%.
Combined Enzyme Tests
The next question investigated was whether the diagnostic value of thesetests can be increased by combining the results of two or more of these enzyme assays. Table 5 shows the predictive value of various combinations, with the results tabulated by number of enzyme tests that were abnormal. Of the patients who had abnormal values for all four enzyme tests, 86.4%, or 19 of 22 patients had metastases. By contrast, only one of 22 patients for whom all four enzyme tests were normal had liver metastases (4.5%). There is a trend: the more enzyme assay results a patient has that are abnormal, the greater is the likelihood of liver metastases.
The best combination of all four enzyme tests was one in which zero or only one abnormal test result was associated with lack of liver metastases, while two or more abnormal tests were associated with its presence. As shown in the lower part of Table 5 , the PV+ of two or more abnormal tests is 66.7%. Table 6 shows the results of combining assay results for5'-nucleotidase and -y-glutamyltransferase. The data show some advantage in doing both tests: if both are normal, the patient is unlikely to have liver metastasis (only one of 31 patients had a false-negative result). If both tests are abnormal, the patient is likely to have liver metastasis (only four of 27 patients had falsepositive results). For these two instances alone, liver metastasis was diagnosed correctly in 53 of 58 patients (91.4%), and the PV+ was 23/27, or 85.2%.
Discussion
The results of our study clearly show that all four enzymes are valuable in the detection of liver metastases. When dichotomized into normal and abnormal, the x2 values were all high, with very small associated P values (Table 4) . Alkaline phosphatase assays showed 71.3% agreement in diagnosing hepatic metastases, a value that compares well with those of 76, 64, and 63% reported by other investigators (11) (12) (13) .
The 33.3% false-positive result shown in our study is lower than the 46% value reported by Fee et al. (13) and the 58% value reported by Uren et al. (12) , although it still emphasizes the nonspecificity of the test. Our false-negative result of 22.5% was more comparable with the value (18%) reported by these workers (12, 13) , the 22% value reported by Mendelsohn and Bodansky (14) , and the 18% of Fenster and Klatskin (15) . However, it was quite different from the 42% value reported by Castagna et al. (16) .
5'-Nucleotidase was the best single test for the detection of liver metastasis in this study: it had the lowest proportion of false-positive results (7.4%), the highest proportion of agreement (81.3%), and the highest PV-I-(85.7%). However, it was the least sensitive of the four enzymes, showing the highest false-negative result (35.1%). This value is greater than that reported by Boone et al. (17) , who found similar false-negative results for 5'-nucleotidase and -y-glutamyltransferase (9 and 12%, respectively). These authors' study, however, included only 16 patients with liver metastases and did not report per cent agreement, per cent false-positive, and PV+ results. The superiority of 5'-nucleotidase was suggested by Smith et al. (18) , who found that measurement of this enzyme is better than alkaline phosphatase for use in the detection of primary or metastatic hepatic malignancy in anicteric patients. Furthermore, Schwartz et al. (19) and Van der Slik et al. (20) indicated that 5'-nucleotidase may be increased at an earlier stage than is alkaline phosphatase, and that high serum alkaline phosphatase activity with normal 5'-nucleotidase activity is strong evidence forthe presence of osteoblastic bone disease. Zein and Discombe (21) and Lum and Gambino (22) reported that -y-glutamyltransferase is of particular value in the diagnosis of liver disease and an extremely sensitive indicator of subtle liver changes. Lum and Gambino (22) also reported that the assay of serum y-giutamyltransferase activity offers a simple, sensitive, and direct means of determining whether bone or liver is the source of increased serum alkaline phosphatase activity. According to other workers (23) (24) (25) , -y-glutamyltransf erase is almost invariably increased in cases with primary or metastatic liver tumors. Rutenberg et al. (26) obtained abnormal values for -y-glutamyltransferase in 59 of 65 patients with hepatic metastases, and only 64% of the patients with abnormal 7-glutamyltransferase results had abnormal alkaline phosphatase. Aronsen et al. (25) , in a study of 153 patients with cancer, showed that y-glutamyltransferase gave a correct diagnosis of liver metastases in 90% of the cases, with false-positive results in 9% and false-negative results in 1% of the cases. These values correspond to a PV+ of 90%. In contrast, Baden et al. (27) found a PV+ of 45% in patients with liver metastasis and were not convinced that either 'y-glutamyltransferase alone or the combination of -y-glutamyltransferase and alkaline phosphatase was reliable in detecting hepatic metastases. These two groups of workers, however, used the same method to determine y-glutamyltransferase activity but different upper limits of normal value (80 and 31.6 U/liter, respectively), which may very well account for their different conclusions.
In our study, 'y-glu- Table 7 , it is apparent that there is improvement in diagnostic value at the higher cutoff values.
Glutamate dehydrogenase is also a liver-specific enzyme and its activity in serum was reported by a number of investigators (3) (4) (5) (6) to correlate with the severity of liver damage in acute and chronic inflammatory disease of the liver. This enzyme has been suggested for the detectionof liver metastases by some of these workers (4, 6), but adequate data are not yet available. According to our study, glutamate dehydrogenase is almost as sensitiveand specific as alkaline phosphatase in detection of heptatic metastases, but inferior to the other two enzymes.
Recently, simultaneous determinations of more than one serum enzyme was used to achieve a better diagnostic value for hepatic metastases. In Aronsen's (25) series of 153 patients with cancer, combined use of the three enzymes, alkaline phosphatase, y-glutamyltransferase, and aspartate aminotransferase gave a correct diagnosis in 93% of cases with liver metastases, which was similar (90%) to that for -y-glutamyltransferase alone. In the study of Castagna et al. (16) , of 13 patients who gave abnormal results for all three liverfunction tests-alkaline phosphatase, albumin, and aspartate aminotransferase-12 (92%) had metastases. Abnormal results for any two of these tests was still associated with a 66.7% presence of metastases, and absence of abnormality in any of the three tests yielded 30.3% false-negative results. Baden et al. (27) also reported that simultaneous determination of alkaline phosphatase and -y-glutamyltransferase offered no improvement in accuracy over the results for either test alone. In the study by Angehrn et a!. (28), the combination of alkaline phosphatase with other blood tests (bilirubin, prothrombin, hemoglobin, and sedimenta-tion rate) did not improve the diagnostic value of alkaline phosphatase alone. In our study, the predictive value of combined determinations was not better statistically than that for any single enzyme test. This was true, however, only if all the patients in our sample (n = 95) were considered. For example, in Table 5 , the presence or absence of liver metastases in patients where all four tests were either abnormal or normal was associated with 86.4 and 4.5% metastasis, respectively, which are relatively good diagnostic values. However, the combined number of patients with metastases included by these two groups was only 20 patients, or 56% of the 36 patients with metastases. Similarly in Table 6 , the per cent agreement in patients where values for 5'-nucleotidase and 7-glutamyltransferase were both either normal or abnormal was excellent (91.4%). However, these two groups included only 24 patients, or 67% of the patients with liver metastasis.
